Zoetis Inc.'s Stock Analysis

Zoetis Reports Fourth Quarter and Full Year 2025 Financials

Zoetis Inc. announced its financial results for the fourth quarter and full year of 2025, reporting revenue of $2.4 billion for Q4, a 3% increase from the previous year, and net income of $603 million, or $1.37 per diluted share, reflecting a 4% and 6% increase respectively. For the full year, the company reported $9.5 billion in revenue, a 2% increase, with net income reaching $2.7 billion, or $6.02 per diluted share, marking an 8% and 10% increase on a reported basis.

The company provided guidance for 2026, anticipating revenue between $9.825 billion and $10.025 billion, with diluted EPS projected between $6.65 and $6.75 on a reported basis. Adjusted net income for the year is expected to range from $2.975 billion to $3.025 billion, indicating organic operational growth of 3% to 6%. The report highlights growth across its product portfolio, particularly in the International segment, which saw an 8% revenue increase, driven by companion animal products and livestock biologics.

Feb 12, 2026 07:04:31

Zoetis Declares $0.53 Dividend for Second Quarter 2026

Zoetis Inc. has announced a dividend of $0.53 per share for the second quarter of 2026. This dividend will be payable on June 2, 2026, to all shareholders on record as of April 20, 2026.

As a leading animal health company, Zoetis generated $9.3 billion in revenue in 2024 and employs approximately 13,800 people. The company focuses on advancing animal care through its portfolio of medicines, vaccines, and diagnostics, serving various stakeholders including veterinarians and livestock producers across over 100 countries.

Feb 05, 2026 16:22:05

Zoetis Raises $2 Billion Through Convertible Senior Notes Offering

Zoetis Inc. has completed a private offering of $2.0 billion in 0.25% Convertible Senior Notes due in 2029. The company plans to use approximately $1.969 billion of the net proceeds for share repurchases, including $248 million to buy 2.1 million shares of its common stock and the remainder for additional repurchases under its existing $6 billion program. The Notes will mature on June 15, 2029, and are convertible under specific conditions, with an initial conversion price set at approximately $148.20 per share.

Additionally, Zoetis entered into capped call transactions to mitigate potential dilution from the Notes' conversion. The capped calls cover around 13.5 million shares and are designed to offset cash payments above the principal amount of converted Notes. A waiver was also secured from lenders under its revolving credit facility to permit early conversions of the Notes. The offering was conducted under exemptions from registration, and the securities involved have not been registered under the Securities Act.

Dec 18, 2025 16:17:38

Zoetis Declares Dividend Increase for First Quarter 2026

Zoetis Inc. has declared a dividend of $0.53 per share for the first quarter of 2026, marking a 6% increase from the previous year's quarterly dividend. This dividend will be paid on March 3, 2026, to shareholders on record as of January 20, 2026.

As a leading company in animal health, Zoetis has a long history of innovation in animal care, providing a range of medicines, vaccines, and diagnostics across more than 100 countries. The company continues to focus on advancing care for animals, impacting veterinarians, pet owners, and livestock producers worldwide.

Dec 11, 2025 16:17:25

Zoetis to Host Innovation Webcast on December 2, 2025

Zoetis Inc. will host an Innovation Webcast on December 2, 2025, at 8:30 a.m. ET, where the company will present insights into its business strategies and market opportunities in the animal health sector. The presentation will cover the anticipated growth of the global animal health market, projected to reach approximately $90 billion by 2035, driven by factors such as an increase in pet ownership, longer pet lifespans, and a rising demand for advanced therapies in both companion animals and livestock.

During the webcast, Zoetis will highlight its robust research and development pipeline, which includes a diverse range of products targeting chronic diseases, oncology, and cardiology in animals. The company aims to maintain its leadership in the market through continuous innovation and strategic collaborations. Key topics will also include advancements in vaccine development and the growing focus on preventative care in livestock, which are expected to drive the company’s future growth and market presence.

Dec 02, 2025 08:00:17

Zoetis Reports Q3 2025 Financial Results and Guidance Update

Zoetis Inc. reported third-quarter revenue of $2.4 billion, marking a 1% increase from the previous year. Net income rose to $721 million, or $1.63 per diluted share, reflecting a 6% increase in net income and a 9% increase in earnings per share compared to Q3 2024. The company achieved 4% organic operational growth in revenue and 9% organic operational growth in adjusted net income for the quarter. Adjusted net income was reported at $754 million, or $1.70 per diluted share, with significant contributions from its companion animal and livestock product portfolios.

For the full year 2025, Zoetis revised its revenue guidance to a range of $9.400 billion to $9.475 billion, anticipating organic operational growth of 5.5% to 6.5%. The company also narrowed its guidance for organic operational growth in adjusted net income to 5.5% to 7.0%. The diluted EPS guidance remains between $6.30 and $6.40. The results reflect the company's ongoing investment in product innovation and strategic operational adjustments to enhance customer engagement and market presence.

Nov 04, 2025 07:06:23

Zoetis Appoints Stephanie Tilenius to Board of Directors

Zoetis Inc. has appointed Stephanie Tilenius to its Board of Directors, effective December 1, 2025, increasing the Board size from twelve to thirteen members. Ms. Tilenius brings extensive experience in digital health and technology, having founded several healthcare companies and held senior positions at major tech firms such as Google, PayPal, and eBay. She will participate in the company's non-employee director compensation program and will also enter into a standard indemnification agreement with Zoetis.

The appointment was announced on October 28, 2025, and is seen as a strategic move to enhance Zoetis' focus on digital transformation and innovation in animal health. Ms. Tilenius' background in leveraging data and artificial intelligence aligns with Zoetis' commitment to improving animal care. Her addition to the Board is expected to provide valuable insights as the company continues to advance its mission in the animal health industry.

Oct 28, 2025 08:33:44

Zoetis Declares $0.50 Dividend for Fourth Quarter 2025

Zoetis Inc. has declared a dividend of $0.50 per share for the fourth quarter of 2025. This dividend will be paid on December 2, 2025, to shareholders who are on record as of the close of business on October 31, 2025.

As a leading company in animal health, Zoetis generated revenue of $9.3 billion in 2024 and has approximately 13,800 employees. The company focuses on advancing care for animals through a wide range of medicines, vaccines, diagnostics, and technologies, serving customers in over 100 countries.

Oct 09, 2025 16:24:08

Zoetis Secures $1.25 Billion Revolving Credit Facility

Zoetis Inc. has entered into a five-year revolving credit agreement with a syndicate of banks, providing for a $1.25 billion senior unsecured credit facility. This agreement replaces the company's previous credit facility and allows for an increase in commitments up to $1.75 billion, subject to certain conditions. The facility includes interest rates based on either a base rate or a term SOFR rate, and it mandates a financial covenant that limits the company's total leverage ratio.

Additionally, the prior credit agreement, effective from December 21, 2022, has been terminated, with all commitments under it also ending. The new credit agreement includes customary covenants that restrict the company's ability to incur additional debt or sell assets, and it allows for voluntary prepayment of loans without penalties. The interest and facility fees are determined based on the company's credit ratings and are payable quarterly.

Aug 27, 2025 16:21:54

Zoetis Issues $1.85 Billion in Senior Notes for Investors

On August 11, 2025, Zoetis announced the issuance and sale of $850 million in 4.150% Senior Notes due 2028 and $1 billion in 5.000% Senior Notes due 2035, collectively referred to as the Notes. This offering was conducted under an Underwriting Agreement with specified underwriters and is registered under a Form S-3 Registration Statement. The Notes are governed by an indenture established with Deutsche Bank Trust Company Americas.

The issuance of these Senior Notes is part of Zoetis's financial strategy and may impact the company's capital structure and liquidity. Investors should consider the terms of the Notes, including their interest rates and maturity dates, as part of their evaluation of the company's financial health and future performance.

Aug 18, 2025 11:43:10